Peptide research profile

KPV

Also known as α-MSH(11-13) · Lys-Pro-Val

The C-terminal tripeptide of alpha-melanocyte-stimulating hormone, studied for anti-inflammatory signaling primarily in cells and mouse colitis models.

  • Repair & regeneration
  • Immune & inflammation
  • Skin & connective tissue
Preclinical-heavy2 referencesEducational use

Dosing literacy

Dosing & scaling, explained

The 200–500 mcg daily rows are recorded research presets. The anchor literature uses cell systems and oral mouse models, not a human injection trial. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Starting pointNot clinically established
    No validated titration window

    There is no regulator-approved starting dose for this research use. A low-looking number is not automatically safe.

  2. Recorded preset200–500 mcg / day
    Calculator library reference

    This is the range represented in the in-app protocol library. It describes the source record; it does not validate the regimen.

  3. Higher exposure500 mcg / day is the high library row
    Risk and uncertainty increase

    Higher exposure is not established as more effective. Human pharmacokinetic and long-term safety data may be absent.

Drug amount and device markings are different quantities. The calculator converts mass into volume, syringe units, or pen clicks.

Schedule literacy

Patterns described in source material

  • Daily in recorded presets

    The cadence represented by the recorded calculator presets.

  • Oral delivery in mouse colitis studies

    Published experiments may use a different route, formulation, timing, or population and should not be treated as interchangeable.

  • No universal schedule

    No single schedule has been validated across products or research contexts.

Clinical context

No randomized human trial establishes dose, route, or efficacy for KPV.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Intestinal inflammation

    DSS, TNBS, and transfer-colitis mouse models are the best-developed research area.

  • 02

    PepT1 transport

    Cell studies examine uptake through the di/tripeptide transporter PepT1.

  • 03

    NF-κB and MAPK signaling

    Laboratory work reports reduced inflammatory-pathway activation and cytokine output.

  • 04

    Barrier-targeted delivery

    Formulation studies explore oral and nanoparticle approaches for intestinal exposure.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Animal

    Multiple mouse colitis models

    KPV reduced selected inflammatory and histologic measures in preclinical intestinal models.

  • In vitro

    Human epithelial and immune cells

    Nanomolar KPV was studied in cytokine-stimulated cell systems with PepT1-dependent uptake.

  • Review

    No established clinical regimen

    Published evidence does not establish injectable efficacy or long-term safety in humans.

Recorded protocol library

Amounts recorded for KPV

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Lower recorded

    200 mcg

    Sign in for schedule, duration and source context.

  • 02

    Dose · upper endpoint

    500 mcg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Melanocortin-derived tripeptide
Sequence
KPV
Amino acids
3
Approx. MW
342.4 Da
Origin / design
Residues 11–13 of α-MSH

Important limitations

  • Mouse colitis outcomes do not establish treatment effects in human inflammatory bowel disease.
  • Oral PepT1-targeted research is not equivalent to an injectable preset.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

2 curated references

  1. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel diseaseInflammatory Bowel Diseases · 2008 · Animal
  2. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationGastroenterology · 2008 · In vitro

Related profiles